{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:46:32Z","timestamp":1792100792812,"version":"4.4.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ijantimicag.2020.106085","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T12:11:07Z","timestamp":1594383067000},"page":"106085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of \u201cBad Bugs, Few Drugs\u201d"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0058-7182","authenticated-orcid":false,"given":"Hien M.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Graber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106085_bib0001","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1128\/AAC.02897-15","article-title":"Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012","volume":"60","author":"Sanchez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0002","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40121-015-0095-5","article-title":"Antimicrobial resistance of Escherichia coli causing uncomplicated urinary tract infections: a European update for 2014 and comparison with 2000 and 2008","volume":"4","author":"Kahlmeter","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0003","first-page":"674","article-title":"Beers Criteria for Potentially Inappropriate Medication Use in Older Adults","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0004","series-title":"FDA advises restricting fluoroquinolone antibiotic use for certai uncomplicated infections; warns about disabling side effects that can occur together","year":"2017"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0005","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/382690","article-title":"\u201cCollateral damage\u201d from cephalosporin or quinolone antibiotic therapy","volume":"38","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0006","article-title":"Antibiotic prescribing choices and their comparative C. difficile infection risks: a longitudinal case-cohort study","author":"Brown","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.ijantimicag.2020.106085_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy198","article-title":"An assessment of inappropriate antibiotic use and guideline adherence for uncomplicated urinary tract infections","volume":"5","author":"Durkin","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0008","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cir102","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0009","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2146\/ajhp150841","article-title":"Why isn't cefadroxil used more often?","volume":"73","author":"Corson","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkw385","article-title":"Role of cephalosporins in the era of Clostridium difficile infection","volume":"72","author":"Wilcox","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0011","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.diagmicrobio.2013.03.022","article-title":"Cephalothin susceptibility testing as class representative for oral cephalosporins: is it time to move on?","volume":"76","author":"Nguyen","year":"2013","journal-title":"Diagn Microb Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0012","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.diagmicrobio.2016.08.017","article-title":"Cephalothin is not a reliable surrogate marker for oral cephalosporins in susceptibility testing of Enterobacteriaceae causing urinary tract infection","volume":"86","author":"L\u00f3pez","year":"2016","journal-title":"Diagn Microb Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0013","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.diagmicrobio.2017.12.007","article-title":"Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae","volume":"90","author":"Bunnell","year":"2018","journal-title":"Diagn Microb Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0014","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12941-017-0217-x","article-title":"Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital","volume":"16","author":"Chastain","year":"2017","journal-title":"Ann Clin Microb Antimicrob"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.diagmicrobio.2013.08.024","article-title":"Cefazolin as a class representative for oral cephalosporins and uncomplicated urinary tract infections caused by indicated Enterobacteriaceae","volume":"77","author":"Schuetz","year":"2013","journal-title":"Diagn Microb Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0016","series-title":"Performance standards for antimicrobial susceptibility testing: 29th informational supplement","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115053","article-title":"Reanalysis of cefazolin surrogate susceptibility breakpoints utilized as guidances for oral cephalosporin treatments of uncomplicated urinary tract infections: caution concerning application to cefadroxil","author":"Nguyen","year":"2020","journal-title":"Diagn Microb Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0018","unstructured":"United States Committee on Antimicrobial Susceptibility Testing (USCAST). Breakpoint tables for interpretation of MIC and zone diameterresults. Version 6.0. http:\/\/www.uscast.org(April 14 2020, date last accessed)."},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1128\/AAC.12.1.93","article-title":"Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin","volume":"12","author":"Hartstein","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0020","unstructured":"US-FDA. Cephalexin (Keflex) package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/050405s097lbl.pdf(April 14 2020, date last accessed)."},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0021","unstructured":"US-FDA. Cefadoxril monohydrate (Duricef) package insert.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/050405s097lbl.pdf(April 14 2020, date last accessed)."},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0022","unstructured":"Institute of Obstetricians and Gynaecologists, Royal College of Physcians of Ireland: Management of Urinary Tract Infections in Pregnancy 2018. https:\/\/rcpi-live-cdn.s3.amazonaws.com\/wp-content\/uploads\/2016\/05\/32.-Management-of-Urinary-Tract-Infections-in-Pregnancy.pdf(April 14 2020, date last accessed)."},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0023","unstructured":"National Institute for Health and Care Excellenc (NICE): Urinary tract infection (lower): antimicrobial prescribing. 2018. https:\/\/www.nice.org.uk\/guidance\/ng109(April 14 2020, date last accessed)."},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0024","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1128\/jcm.17.6.1156-1158.1983","article-title":"Comparison of the antibacterial spectra of cephalexin and cefaclor with those of cephalothin and newer cephalosporins: reevaluation of the class representative concept of susceptibility testing","volume":"17","author":"Preston","year":"1983","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0025","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1128\/jcm.27.7.1460-1463.1989","article-title":"Comparison of cefadroxil and cephalothin disk susceptibility test results","volume":"27","author":"Barry","year":"1989","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0026","first-page":"9","article-title":"The antimicrobial activity of cephalexin against old and new pathogens","volume":"59","author":"Jones","year":"1983","journal-title":"Postgrad Med J"},{"issue":"13","key":"10.1016\/j.ijantimicag.2020.106085_bib0027","first-page":"67","article-title":"beta-lactamase production by strains of Escherichia coli of intermediate susceptibility to beta-lactam antibiotics. A study of their clinical significance in urinary tract infection","author":"Brauner","year":"1978","journal-title":"Scand J Infect Dis Suppl"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0028","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1128\/AAC.38.11.2612","article-title":"Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women","volume":"38","author":"Elhanan","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0029","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0924-8579(99)00118-1","article-title":"Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection","volume":"13","author":"Menday","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jama.1995.03520250057034","article-title":"Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women","volume":"273","author":"Hooton","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0031","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/infdis\/153.2.277","article-title":"Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women","volume":"153","author":"Greenberg","year":"1986","journal-title":"J Infect Dis"},{"issue":"135","key":"10.1016\/j.ijantimicag.2020.106085_bib0032","first-page":"138","article-title":"Treatment of urinary tract infection with cephalexin","volume":"17","author":"Kostas","year":"1983","journal-title":"J Fam Pract"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0033","doi-asserted-by":"crossref","first-page":"S629","DOI":"10.1007\/BF01639685","article-title":"Clinical comparison of cefadroxil and cephalexin in uncomplicated urinary tract infection","volume":"8","author":"Henness","year":"1980","journal-title":"Infect"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0034","first-page":"97","article-title":"Treatment of acute uncomplicated urinary tract infections by cephalexin, with special reference to the antibody-coated bacteria","volume":"20","author":"Iravani","year":"1982","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0090-4295(78)90397-7","article-title":"Clinical comparison of cefadroxil, new oral cephalosporin, and cephalexin in uncomplicated urinary tract infection","volume":"12","author":"Bolding","year":"1978","journal-title":"Urology"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0036","first-page":"319","article-title":"The treatment of bacterial cystitis, comparing cephalexin with sulfisoxazole","volume":"19","author":"Brewin","year":"1971","journal-title":"J Am Coll Health Assoc"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0037","first-page":"212","article-title":"Cephalexin: clinical and laboratory studies with 500 mg twice daily dosage in urinary infection. Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie","volume":"4","author":"Montgomery","year":"1971","journal-title":"Int J Clin Pharmaco Ther Toxicol"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0038","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/bmj.2.5815.673","article-title":"Double-blind trial to compare ampicillin, cephalexin, co-trimoxazole, and trimethoprim in treatment of urinary infection","volume":"2","author":"Brumfitt","year":"1972","journal-title":"Br Med J"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0039","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/bmj.1.6011.684","article-title":"Comparative double-blind study of cephalexin and co-trimoxazole in urinary tract infections","volume":"1","author":"Gower","year":"1976","journal-title":"Br med J"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0040","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000220697","article-title":"Clinical evaluation of cephalexin in the treatment of urinary tract infections","volume":"15","author":"Eyckmans","year":"1970","journal-title":"Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0041","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bmj.3.5768.215","article-title":"Comparative double-blind trial of cephalexin and ampicillin in treatment of urinary infections","volume":"3","author":"Davies","year":"1971","journal-title":"Br Med J"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0042","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1128\/AAC.4.6.593","article-title":"Double-blind comparison of carbenicillin indanyl sodium, ampicillin, and cephalexin in treatment of urinary tract infection","volume":"4","author":"Ries","year":"1973","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0043","article-title":"Antimicrobial agents for treating uncomplicated urinary tract infection in women","author":"Trestioreanu","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0044","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/cid\/cis688","article-title":"White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens","volume":"55","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/10.suppl_B.77","article-title":"The role of cefadroxil in the therapy of urinary tract infections","volume":"10","author":"Wilber","year":"1982","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0046","doi-asserted-by":"crossref","DOI":"10.12788\/jhm.2904","article-title":"The Maturing Antibiotic Mantra:\u201cShorter Is Still Better\u201d","volume":"13","author":"Spellberg","year":"2018","journal-title":"J Hosp Med"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0047","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkq237","article-title":"Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials","volume":"65","author":"Falagas","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0048","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/030006057800600604","article-title":"An overview of results of world-wide clinical trials with cefadroxil","volume":"6","author":"Santella","year":"1978","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0049","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jac\/10.suppl_B.65","article-title":"Evaluation of cefadroxil in complicated and uncomplicated infections of the upper and lower urinary tract","volume":"10","author":"Flores","year":"1982","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0050","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0924-8579(02)00105-X","article-title":"Correlation between pharmacokinetic\/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection","volume":"19","author":"Frimodt-M\u00f8ller","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.03.001","article-title":"Optimizing dosing of nitrofurantoin from a PK\/PD point of view: what do we need to know?","author":"Wijma","year":"2019","journal-title":"Drug Resistance Updates"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02560-17","article-title":"Pharmacokinetics and pharmacodynamics of fosfomycin and its activity against extended-spectrum-\u03b2-lactamase-, plasmid-mediated AmpC-, and carbapenemase-producing Escherichia coli in a murine urinary tract infection model","volume":"62","author":"Zykov","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0053","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijid.2017.03.012","article-title":"Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis","volume":"58","author":"Pinart","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0054","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.4172\/2167-7700.1000e105","article-title":"Do we need PK\/PD in the treatment of urogenital infections","volume":"1","author":"Wagenlehner","year":"2012","journal-title":"Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/1120009X.2017.1380357","article-title":"Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections","volume":"29","author":"Novelli","year":"2017","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0057","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of \u03b2-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0058","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.49.9.3944-3947.2005","article-title":"Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem","volume":"49","author":"Bhavnani","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0059","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1128\/AAC.01133-08","article-title":"Urinary bactericidal activity of doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis","volume":"53","author":"Wagenlehner","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0060","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10096-019-03679-9","article-title":"A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis","volume":"38","author":"Cattrall","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0061","article-title":"965: The Efficacy of Oral Beta-lactam Antibiotics as Step-down Therapy for Acute Pyelonephritis. IDWeek 2019 Oral Poster","volume":"6","author":"Hobbs","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0062","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz359.033","article-title":"848: Low-bioavailability vs. high-bioavailability oral antibiotics for the definitive treatment of Enterobacteriaceae bacteremia from suspected urine source in hospitalized veterans. IDWeek 2019 Oral Poster","volume":"6","author":"Sutton","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0063","unstructured":"Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Sixth Edition. London, UK: Hodder Arnold Ltd; 2010."},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0064","series-title":"In vivo PK\/PD of mecillinam in a murine urinary tract infection (UTI) model","author":"Vingsbo Lundberg","year":"2009"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0065","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/AAC.47.3.1002-1009.2003","article-title":"Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse model","volume":"47","author":"Kerrn","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.11.008","article-title":"Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model","volume":"55","author":"Zykov","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0067","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1128\/AAC.00182-11","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106085_bib0068","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2019.05.013","article-title":"Urinary piperacillin\/tazobactam pharmacokinetics in-vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriacae","volume":"54","author":"Gould","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0069","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/(SICI)1099-081X(199605)17:4<319::AID-BDD957>3.0.CO;2-W","article-title":"A pharmacokinetic comparison of cefadroxil and cephalexin after administration of 250, 500 and 1000 mg solution doses","volume":"17","author":"Barbhaiya","year":"1996","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1128\/AAC.12.2.157","article-title":"Comparative pharmacology of cefaclor and cephalexin","volume":"12","author":"Korzeniowski","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0071","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1128\/AAC.11.2.331","article-title":"Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine","volume":"11","author":"Pfeffer","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0072","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/bdd.2510060206","article-title":"A pharmacokinetic comparison of cephalexin and cefadroxil using HPLC assay procedures","volume":"6","author":"Welling","year":"1985","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0073","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijantimicag.2005.02.012","article-title":"Bactericidal activity of oral \u03b2-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad-and extended-spectrum \u03b2-lactamases","volume":"25","author":"Bedenic","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0074","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1128\/CMR.5.4.420","article-title":"Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance","volume":"5","author":"Peterson","year":"1992","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0075","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1469-0691.1998.tb00083.x","article-title":"The bactericidal activity of gatifloxacin in plasma and urine","volume":"4","author":"Wise","year":"1998","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0076","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1093\/jac\/dkw212","article-title":"Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections","volume":"71","author":"Fransen","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0077","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000095969","article-title":"Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model","volume":"52","author":"Bedenic","year":"2006","journal-title":"Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0078","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","article-title":"Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women","volume":"29","author":"Warren","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0079","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/jac\/48.6.895","article-title":"Antibiotic failure in the treatment of urinary tract infections in young women","volume":"48","author":"Lawrenson","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0080","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0081","doi-asserted-by":"crossref","first-page":"c199","DOI":"10.1136\/bmj.c199","article-title":"Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial","volume":"340","author":"Little","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0082","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw217","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0083","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajem.2017.06.041","article-title":"Risk factors for early return visits to the emergency department in patients with urinary tract infection","volume":"36","author":"Jorgensen","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0084","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00203-19","article-title":"Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories","volume":"57","author":"Humphries","year":"2019","journal-title":"J Clinical Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/jcm9010157","article-title":"Definitive cefazolin therapy for stabilized adults with community-onset Escherichia coli, Klebsiella Species, and Proteus mirabilis bacteremia: MIC matters","volume":"9","author":"Hsieh","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0086","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/cid\/cir031","article-title":"Subcommittee on antimicrobial susceptibility testing of the clinical and laboratory standards institute. Cefazolin and enterobacteriaceae: rational for revised susceptibility testing breakpoints","volume":"52","author":"Turnidge","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0087","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0089","series-title":"SHC Clinical Pathway: Management of Urinary Tract Infections \u2013 Adult Patients","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0090","unstructured":"Short Course Therapy for Urinary Tract Infections in Children Trial (SCOUT) NCT01595529. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01595529(April 14 2020, date last accessed)."},{"key":"10.1016\/j.ijantimicag.2020.106085_bib0091","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116207","article-title":"Compliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials","volume":"10","author":"Falagas","year":"2015","journal-title":"PLoS One"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:38:34Z","timestamp":1760377114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920302557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0924857920302557"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106085","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of \u201cBad Bugs, Few Drugs\u201d","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106085"}}